283 related articles for article (PubMed ID: 17314277)
1. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Zheng C; Khoo C; Ikewaki K; Sacks FM
J Lipid Res; 2007 May; 48(5):1190-203. PubMed ID: 17314277
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
4. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
Sacks FM
Curr Opin Lipidol; 2015 Feb; 26(1):56-63. PubMed ID: 25551803
[TBL] [Abstract][Full Text] [Related]
5. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
Campos H; Perlov D; Khoo C; Sacks FM
J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
[TBL] [Abstract][Full Text] [Related]
6. Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III.
Zheng C; Khoo C; Furtado J; Ikewaki K; Sacks FM
Am J Clin Nutr; 2008 Aug; 88(2):272-81. PubMed ID: 18689361
[TBL] [Abstract][Full Text] [Related]
7. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
9. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
[TBL] [Abstract][Full Text] [Related]
10. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.
Khoo C; Campos H; Judge H; Sacks FM
J Lipid Res; 1999 Feb; 40(2):202-12. PubMed ID: 9925648
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
Ooi EM; Chan DC; Hodson L; Adiels M; Boren J; Karpe F; Fielding BA; Watts GF; Barrett PH
Eur J Clin Invest; 2016 Aug; 46(8):730-6. PubMed ID: 27378472
[TBL] [Abstract][Full Text] [Related]
12. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
[TBL] [Abstract][Full Text] [Related]
13. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
Sehayek E; Eisenberg S
J Biol Chem; 1991 Sep; 266(27):18259-67. PubMed ID: 1917954
[TBL] [Abstract][Full Text] [Related]
15. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS
J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287
[TBL] [Abstract][Full Text] [Related]
16. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
17. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
[TBL] [Abstract][Full Text] [Related]
18. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
Breyer ED; Le NA; Li X; Martinson D; Brown WV
J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
[TBL] [Abstract][Full Text] [Related]
20. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
